|
| 35995710 | Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. | Eur Urol Oncol | 2023 |
| 37527013 | SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. | Clin Cancer Res | 2023 |
| 37581614 | SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. | Clin Cancer Res | 2023 |
| 37932451 | CRISPR-Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames. | Nat Struct Mol Biol | 2023 |
| 37097293 | TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses. | J Exp Med | 2023 |
| 37462917 | Correction: TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses. | J Exp Med | 2023 |
| 35241842 | Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. | Nat Med | 2022 |
| 35847448 | Lentiviral interferon: A novel method for gene therapy in bladder cancer. | Mol Ther Oncolytics | 2022 |
| 35595730 | Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. | Blood Cancer J | 2022 |
| 35484266 | Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. | Nat Med | 2022 |
| 36525493 | EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. | Sci Adv | 2022 |
| 36212401 | Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. | Front Oncol | 2022 |
| 35913398 | Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6. | Cancer Res | 2022 |
| 33414133 | ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. | Clin Cancer Res | 2021 |
| 34158347 | PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. | Mol Cancer Ther | 2021 |
| 34117863 | Methylation-eQTL analysis in cancer research. | Bioinformatics | 2021 |
| 34168048 | ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. | Clin Cancer Res | 2021 |
| 33356422 | Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). | J Clin Oncol | 2021 |
| 32236410 | Role of CX3CR1 signaling in malignant transformation of gliomas. | Neuro Oncol | 2020 |
| 32977531 | FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. | Noncoding RNA | 2020 |
| 32576626 | The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. | Clin Cancer Res | 2020 |
| 32366834 | Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. | Blood Cancer J | 2020 |
| 32122956 | TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. | Mol Cancer Res | 2020 |
| 32358507 | Effective combinatorial immunotherapy for penile squamous cell carcinoma. | Nat Commun | 2020 |
| 30666052 | PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. | Mod Pathol | 2019 |
| 31640780 | Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. | J Immunother Cancer | 2019 |
| 29947810 | The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. | J Natl Cancer Inst | 2019 |
| 31439587 | PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2019 |
| 31182807 | The deubiquitinase Otub1 controls the activation of CD8<sup>+</sup> T cells and NK cells by regulating IL-15-mediated priming. | Nat Immunol | 2019 |
| 30745366 | Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. | Cancer Immunol Res | 2019 |
| 30352910 | DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. | Clin Cancer Res | 2019 |
| 28745330 | Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. | Leukemia | 2018 |
| 30059495 | Bayesian variable selection with graphical structure learning: Applications in integrative genomics. | PLoS One | 2018 |
| 30268436 | A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. | Cell Syst | 2018 |
| 29689244 | Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. | Hum Pathol | 2018 |
| 29734016 | Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. | Neoplasia | 2018 |
| 27074575 | Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma. | Oncotarget | 2017 |
| 28281555 | NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. | Mod Pathol | 2017 |
| 28228262 | Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. | Cell Rep | 2017 |
| 28356390 | The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. | J Exp Med | 2017 |
| 28267766 | Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. | PLoS One | 2017 |
| 28936799 | Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. | Ann Surg Oncol | 2017 |
| 28627414 | AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. | Am J Pathol | 2017 |
| 28536297 | Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. | Sci Signal | 2017 |
| 28851898 | Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. | Sci Rep | 2017 |
| 28817403 | Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. | Am J Surg Pathol | 2017 |
| 27568520 | Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. | Leukemia | 2017 |
| 27053917 | Integrative Analysis of mRNA, microRNA, and Protein Correlates of Relative Cerebral Blood Volume Values in GBM Reveals the Role for Modulators of Angiogenesis and Tumor Proliferation. | Cancer Inform | 2016 |
| 26573234 | Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. | Oncotarget | 2016 |
| 26308769 | Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. | Leukemia | 2016 |